Anabolic therapy in glucocorticoid-induced osteoporosis

New England Journal of Medicine

Volumn 357, Issue 20, 2007, Pages 2084-2086

  Sambrook, Philip N ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; CALCIUM; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; VITAMIN D;

BONE DENSITY; BONE REMODELING; BONE TURNOVER; CELL DIFFERENTIATION; CELL GROWTH; DIZZINESS; EDITORIAL; HEADACHE; HIP FRACTURE; HUMAN; INJECTION SITE REACTION; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RIB FRACTURE; SPINE FRACTURE; VERTEBRA FRACTURE;

EID: 36148956531     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe0706770     Document Type: Editorial

References (10)

1. Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral glucocorticoids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
2. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39.
3. Canalis E, Mazziotti G, Giustina A, Bilzekian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007;18:1319-28.
4. Weinstein RS, Jilka RL, Parfitt AF, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone. J Clin Invest 1998;102:274-82.
5. Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R. Glucocorticoid suppresses the canonical Wnt pathway in cultured human osteoblasts. Biochem Biophys Res Commun 2005;329:177-81.
6. Sambrook PN, Hughes DR, Nelson AE, Robinson BG, Mason RS. Osteocyte viability with glucocorticoid therapy: relation to histomorphometry. Ann Rheum Dis 2003;62:1215-7.
7. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent glucocorticoid-induced osteoporosis. N Engl J Med 1997;337:382-7.
8. Saag KG, Emkey R, Schnitzler TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.
9. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-85.
10. Naganathan V, Jones G, Nash P, Nicholson G, Eisman J, Sambrook PN. Vertebral fracture risk with long term glucocorticoids: prevalence, relationship to age, bone density, and glucocorticoid use. Arch Intern Med 2000;160:2917-22.